Epilepsy Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Growing Demand for Anti-Epileptic Drugs (AEDs)
   3. Market Restraints
      1. Limited Treatment Accessibility in Low-Income Regions
      2. Adverse Effects and Compliance Issues
   4. Market Opportunities
      1. Advancements in Brain Stimulation Therapies
   5. Market Trends
      1. Personalized Medicine and Targeted Therapies
      2. Integration of Digital Health Solutions
5. MARKET SEGMENTATION
   1. By Condition
      1. Epilepsy Drug Resistant/Intractable Epilepsy
      2. Others
   2. By Drug
      1. First-Generation
      2. Second-Generation
      3. Third-Generation
   3. By Distribution Channel
      1. Hospitals
      2. Clinics
      3. Retail Pharmacies
      4. Online Pharmacies
   4. By End User
      1. Hospitals
      2. Clinics
      3. Ambulatory Surgical Centers
      4. Diagnostic Centers
   5. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Abbott (U.S.)
      2. Bausch Health Companies Inc. (Canada)
      3. DAIICHI SANKYO COMPANY LIMITED (Japan)
      4. Eisai Co. Ltd (Japan)
      5. GSK plc (U.K.)
      6. H. Lundbeck A/S (Denmark)
      7. Johnson & Johnson Services Inc. (U.S.)
      8. Marinus Pharmaceuticals Inc. (U.S.)
      9. Novartis AG (Germany)
      10. Neurelis Inc. (U.S.)
      11. Pfizer Inc. (U.S.)
      12. Sumitomo Dainippon Pharma Co. Ltd (Japan)
      13. Sanofi (France)
      14. Supernus Pharmaceuticals Inc (U.S.)
      15. Teva Pharmaceutical Industries Ltd. (U.S.)
      16. Takeda Pharmaceutical Company Limited (Japan)
      17. UCB S.A. (China)
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Epilepsymarket?

The global market of Epilepsy is projected to reach USD 4482.34 Mn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Epilepsymarket?

The global Epilepsy market has an estimated annual growth rate of 6.9% .

Q.3. What are the recent trends of Epilepsymarket?

Personalized medicine and targeted therapies and integration of digital health solutions are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Epilepsy?

The major companies profiled in this report include Abbott (U.S.), Bausch Health Companies Inc. (Canada), DAIICHI SANKYO COMPANY LIMITED (Japan), Eisai Co. Ltd (Japan), GSK plc (U.K.), H. Lundbeck A/S (Denmark), Johnson & Johnson Services Inc. (U.S.), Marinus Pharmaceuticals Inc. (U.S.), Novartis AG (Germany), Neurelis Inc. (U.S.), Pfizer Inc. (U.S.), Sumitomo Dainippon Pharma Co. Ltd (Japan), Sanofi (France), Supernus Pharmaceuticals Inc (U.S.), Teva Pharmaceutical Industries Ltd. (U.S.), Takeda Pharmaceutical Company Limited (Japan), UCB S.A. (China), among others.

Q.5. Which region is estimated to held highest CAGR inEpilepsymarket?

North America is estimated to hold biggest share in the market for Epilepsy.